Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients.
Satoru
S
Takeuchi
Kojiro
K
Wada
Kimihiro
K
Nagatani
Naoki
N
Otani
Hideo
H
Osada
Hiroshi
H
Nawashiro
D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000009:adverse effects; D002545:Brain Ischemia / Q000188:drug therapy* / Q000453:epidemiology; D000069604:Dabigatran; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D007275:Injections, Intravenous / Q000379:methods; D012307:Risk Factors; D020521:Stroke / Q000188:drug therapy* / Q000453:epidemiology; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
D000925:Anticoagulants; D001562:Benzimidazoles; D005343:Fibrinolytic Agents; D015091:beta-Alanine; D010959:Tissue Plasminogen Activator; D000069604:Dabigatran